Last reviewed · How we verify
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with daratumumab, bortezomib, and dexamethasone, and how well they work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoclax with daratumumab, bortezomib, and dexamethasone may work better in treating patients with relapsed or refractory multiple myeloma compared to standard of care treatment, including chemotherapy.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | WITHDRAWN |
| Start date | Fri Jan 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu May 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Interventions
- Bortezomib
- Daratumumab
- Dexamethasone
- Venetoclax
Countries
United States